“Demand will outstrip supply for the next five years in Germany”
Chinook’s goal is to provide medical
cannabis formulations and dose delivery
systems for German patients.
Chinook Tyee Industry Ltd. has arranged a non-brokered placement of up to 10 million common shares at a price of 15 cents per share for gross proceeds of up to $1.5-million for working capital purposes. All securities issued pursuant to the offering will be subject to a statutory hold period of four months plus a day from issuance in accordance with applicable securities laws. Chinook expects to complete the offering on or before June, 2019.
About Chinook Tyee Industry Ltd.
Chinook is a Berlin-based investment company with two European subsidiaries, AMP Alternative Medical Products GmbH (AMP) and Mercury Partners & Company PLC. AMP plans to import pharmaceutical-grade cannabis produced by Canadian-licensed producers into Germany. AMP in co-operation with its business partners will provide European Union good manufacturing practice audit, logistical, transportation, importation and other related services for the importation of medical cannabis into Germany.
We seek Safe Harbor.